The rhomboid protease family: a decade of progress on function and mechanism
© BioMed Central Ltd 2011
Published: 27 October 2011
Skip to main content
© BioMed Central Ltd 2011
Published: 27 October 2011
Rhomboid proteases are the largest family of enzymes that hydrolyze peptide bonds within the cell membrane. Although discovered to be serine proteases only a decade ago, rhomboid proteases are already considered to be the best understood intramembrane proteases. The presence of rhomboid proteins in all domains of life emphasizes their importance but makes their evolutionary history difficult to chart with confidence. Phylogenetics nevertheless offers three guiding principles for interpreting rhomboid function. The near ubiquity of rhomboid proteases across evolution suggests broad, organizational roles that are not directly essential for cell survival. Functions have been deciphered in only about a dozen organisms and fall into four general categories: initiating cell signaling in animals, facilitating bacterial quorum sensing, regulating mitochondrial homeostasis, and dismantling adhesion complexes of parasitic protozoa. Although in no organism has the full complement of rhomboid function yet been elucidated, links to devastating human disease are emerging rapidly, including to Parkinson's disease, type II diabetes, cancer, and bacterial and malaria infection. Rhomboid proteases are unlike most proteolytic enzymes, because they are membrane-immersed; understanding how the membrane immersion affects their function remains a key challenge.
Proteolysis within the membrane was discovered in seemingly rare contexts nearly 15 years ago [1–3]. It is now widely appreciated that this fascinating regulatory paradigm permeates most areas of modern cell biology [4–7]. Of the three protease families that catalyze intramembrane proteolysis, rhomboid enzymes are the only family that were not discovered from the direct study of human disease. The name 'rhomboid' has its origin deep in the rich folklore of Drosophila genetics. Rhomboid emerged from the historic quest to identify all genes required to organize construction of a free-living organism from a single cell [8, 9]. Because genes were named after the altered appearance of the mutant larval cuticle, the mis-shaped, rhombus-like head skeleton of the mutant embryo earned rhomboid its name. Mutating the growth factor that rhomboid activates yielded indistinguishable head-skeleton defects, and was named spitz ('pointed' in German).
The rhomboid gene was cloned and sequenced by Bier and colleagues in 1990, revealing a seven transmembrane (7TM) protein with no homology to any sequence known at the time . The spitz sequence was more informative, encoding a clear epidermal growth factor (EGF)-like protein . The fact that rhomboid mirrored spitz phenotypically , and encoded a seven TM protein, led to the proposal that it might be a serpentine receptor for Spitz signaling . But as sequencing of genomes from diverse organisms began to reveal rhomboid homologs in every form of cellular life , it became clear that rhomboid proteins may be at the core of very diverse biological regulation.
Sequence analysis, however, yielded no clues about the underlying biochemical function of rhomboid proteins, and no other homologs were as well studied as Drosophila rhomboid. A decade of Drosophila genetics had, however, set the stage for a biochemical approach: rhomboid was definitively implicated as an upstream activator of Spitz in the signal-sending cell, providing a framework for analyzing its molecular function [12–15]. A focused analysis of Spitz activation eventually yielded four key pieces of the puzzle : (i) substochiometric levels of Rhomboid triggered Spitz proteolysis, implying that Rhomboid acts enzymatically; (ii) proteolysis depends absolutely only on four Rhomboid residues, and their identity is consistent with serine protease catalysis; (iii) Spitz proteolysis is blocked only by serine protease inhibitors; and (iv) Spitz is cleaved within its TM segment at a depth similar to that of the putative rhomboid catalytic serine. These pieces fit together into a model in which rhomboid acts as an intramembrane serine protease for Spitz , which was confirmed 4 years later by reconstituting cleavage with pure proteins [17–19].
Known rhomboid protease substrates and functions across evolution
EGFR signaling (embryo, most developing tissues, adult)
EGFR signaling in oocyte, germline
EGFR signaling in embryo, eye disc
Mitochondrial fusion, mitophagy
Amplifying EGFR signaling (vulva)
Activating twin-arginine translocon, quorum sensing
Mitochondrial membrane fusion, pre-sequence removal
Homo sapiens Mus musculus
Downregulating mitophagy, crista remodeling, anti-apoptosis
TM, EphrinB1,2,3, EGF
Blood clotting? Cell migration? Cancer?
EBA175, TRAP, other adhesins
AMA1, MIC2, MIC6
AMA1, MIC2, MIC6
Phagocytosis, immune evasion
In addition to the number of TMs, two further variations provide potential for additional rhomboid diversity. First, in all three forms, the cytosolic amino termini are highly variable, ranging from large domains to being non-existent. The implications, however, remain unclear, at least partly because achieving well-diffracting crystals required absence of this domain, making its relationship to the catalytic core speculative. On the simplest level, these domains may house sorting signals .
Secondly, rhomboid proteins are often encountered that clearly lack catalytic residues. These should be considered rhomboid proteins but not rhomboid proteases. Two predominant clusters are a distinct 6+1TM form in animals, called iRhom proteins [22, 41], and a 6TM form that is represented widely in eukaryotes by the Derlin proteins [42–45]. Both of these have been implicated in endoplasmic reticulum-associated degradation (ERAD). Derlins have clear sequence homology near the membrane-submerged L1 loop, but also less conspicuously along their entire length, and are thus likely to adopt a GlpG-like 6TM structure. Although clearly not proteolytic, their potential similarity to other aspects of the rhomboid protease mechanism should not be discounted at this early stage (but lie beyond the scope of this review).
First, rhomboid proteases initiate animal cell signaling by releasing growth factors from the membrane. This function emerged from detailed genetic study of Drosophila development; rhomboid proteases are localized in the Golgi apparatus and act as the signal-generating component by cleaving Spitz to initiate the pathway in neighboring cells [16, 46]. Although a role in regulating EGF signaling is also seen in Caenorhabditis elegans vulval development, CeROM-1 has a surprisingly minor role as a target of EGF signaling that sets up a paracrine loop to amplify and spread the signal . Even less is clear in mammals: recent investigations have localized rhomboid proteins to the secretory pathway and cell surface and begun to uncover increased rhomboid expression in cancer cells with potential links to growth factor signaling [24, 48, 49]. However, this is not limited to active rhomboid proteases; expression of the iRhom RHBDF1, which is localized in the endoplasmic reticulum in human epithelial cancer cells, increased secretion of the EGF ligand transforming growth factor-α . Accordingly, RHBDF1 silencing decreased pathway activation through EGF receptor (EGFR), ERK and AKT phosphorylation, and limited tumor growth in mice . The Drosophila homolog, however, was recently found to have the opposite effect of decreasing EGFR signaling by promoting the ERAD-mediated degradation of EGF ligands . The basis of this remarkable discrepancy is currently unclear; knockout mouse studies are expected to provide clarity on the physiological roles of rhomboid proteins.
Recent studies have also placed the mitochondrial rhomboid protease at the nexus of key pathways that govern mitochondrial fusion, mitophagy and apoptosis. All mitochondrial rhomboid proteins are encoded in the nuclear genome, and imported into mitochondria. The main function of the mitochondrial rhomboid Pcp1 is to release the dynamin-like GTPase Mgm1 from the membrane [28, 52, 53]. Because Mgm1 is essential for mitochondrial fusion and Mgm1 cleavage occurs only in healthy mitochondria, this limits fusion to occurring between healthy organelles . A similar function was described in Drosophila , but genetic interactions soon revealed further complexity in metazoans; the mitochondrial rhomboid DmRho-7 also participates in the Parkin/PINK1 pathway that malfunctions in Parkinson's disease . It has recently become clear that the human mitochondrial rhomboid PARL cleaves PINK1 to suppress its ability to recruit the Parkin ubiquitin ligase onto mitochondria [56–58]. Without PARL cleavage, PINK1 accumulates in mitochondria and fails to be recruited properly to damaged mitochondria. A PARL knockout mouse suffers tremendous atrophy several months after birth resulting from malformed mitochondria and elevated apoptosis, although without mitochondrial fusion defects . PARL has also been implicated in suppressing apoptosis in lymphocytes, potentially through a different substrate, High-temperature regulated A (HtrA, also called Omi) . Intriguingly, mutations in PARL have recently been found in Parkinson's disease patients  and diabetes patients , although the significance of these mutations for disease remains speculative.
The third category of rhomboid function was revealed in Providencia stuartii, a Gram-negative bacterial pathogen. Genetic screens identified its rhomboid homolog, AarA, to be required for production of an unidentified signal for quorum sensing [61, 62]. Once the similarity to rhomboid was noted , proteolytic activity of AarA was demonstrated against Spitz , and AarA was found to partially rescue tissue development of Drosophila mutant in rhomboid . Historically, the intriguing similarity of activating Drosophila EGF signaling and producing an auto-inducer for bacterial quorum sensing, both by a rhomboid, received much attention [63, 65]. But the similarity proved to be superficial when the substrate was identified to be TatA, a component of the twin-arginine translocation machinery . As such, AarA removes a short amino-terminal extension, presumably to activate the machinery for signal secretion, rather than activating the signal itself. TatA from other bacteria, including E. coli, lacks this short extension and is immediately active, and the AarA function is therefore an exception. Nevertheless, this is the only known function for a rhomboid protease in any prokaryote, and it dramatically highlights the apparent diversity of rhomboid function even within similar bacteria.
Finally, rhomboid proteases help to dismantle adhesive junctions in unicellular eukaryotic parasites. This is the only role that was discovered by searching for rhomboid targets using substrate specificity determinants . The adhesins of Plasmodium and Toxoplasma are necessary for host-cell invasion, making them essential proteins for the survival of these obligate intracellular parasites . These parasites encode six or more rhomboid proteases, two of which in each organism are known to process these adhesins at the end of the invasion program [25, 26, 68–70]. The precise need for this dismantling is not entirely clear, but has been thought to free the parasite from being tethered to the host plasma membrane. Recent knockdown experiments indicate that this processing is important for efficient invasion , although the full extent is incompletely understood and may involve later functions during parasite replication within the host cell . Even the non-cell-invasive Entamoeba histolytica encodes a highly active rhomboid protease, which is localized to the parasite surface but which relocalizes to phagosomes during feeding and the bud neck during immune evasion, perhaps to shed surface proteins, including lectins [73, 74]. The functions of other Plasmodium or Toxoplasma rhomboid proteases not involved in invasion are not yet understood , and many other parasites encode rhomboid enzymes whose functions have never been explored.
Perhaps the most powerful, yet subtle, guiding principle that can be deduced from the near ubiquity of rhomboid proteases is that they possess a biochemical property that is both very rare and highly useful: but what? Solving this riddle requires understanding the enzymatic features of rhomboid proteases, and remarkable progress has been made towards these goals (reviewed in ).
There is now proof beyond doubt that rhomboid enzymes are serine proteases. This includes reconstitution of proteolysis with pure proteins [17, 19], protease inhibitor profiling [16, 17, 76], extensive analysis of residues essential for activity [16, 18, 19, 77], and structural visualization of catalytic residues and with a covalently bound inhibitor [34–37, 78]. Moreover, the initial paradox of how water is delivered to the membrane-immersed active site for hydrolysis was largely addressed by structural analyses [34–37]: the active site lies submerged about 10 Å below the presumed membrane surface, but with an open cavity above the active site for water access (Figure 3).
Structure-function analyses of rhomboid proteases have also revealed several unusual proteolytic properties that make them unlike most serine proteases. These differences are clear evidence of convergent evolution to a serine protease mechanism down an independent path. First, structural analysis indicates that nucleophilic catalysis is achieved by a histidine-serine catalytic pair, rather than the more common aspartate-histidine-serine catalytic triad [34–37]. Catalytic dyads have been noted in a minority of exceptional serine proteases . The identity of the residues that stabilize the oxyanion transition state is uncertain, but this stabilization is most likely mediated by asparagine and/or histidine side-chains [36, 78] (Figure 3). Use of an asparagine for oxyanion stabilization is uncommon but strikingly analogous to the mechanism of the conventional serine protease subtilisin .
The third unusual catalytic property of rhomboid proteases relates to the direction in which substrates lie across the active site cleft relative to the catalytic residues. Although initially thought to be similar to nearly all other serine proteases [34, 37], identification of the substrate gate on the opposite side of GlpG relative to expectation mandated that substrates approach the catalytic residues from the so-called 'si' face [35, 77, 81]. This stereochemical arrangement is very uncommon and had only been encountered in α/β-hydrolyses . Consistent with this stereochemistry are rhomboid's resistance to most canonical serine protease inhibitors and a weak but specific sensitivity to monocyclic β-lactams [16, 17, 76]. It should be stressed that the definitive evidence for substrate orientation, identity of the oxyanion hole, and the nature of substrate stabilization await a co-structure with a peptide substrate.
Rhomboid proteases have been studied largely within the framework of an established serine protease precedent as a way to interpret rhomboid mechanism, which is instructive but does not help to understand how they are different. Although deciphering the specifics of the catalytic chemistry is essential for designing effective inhibitors, the key functional properties of rhomboid enzymes that are relevant to the cell are unlikely to be determined by its catalytic mechanism. These defining features most likely result from membrane-immersion of the enzyme, and more recent investigations have started to study rhomboid proteases as integral membrane proteins directly.
The greatest impact of membrane immersion is on how substrates and rhomboid proteases behave (as reviewed in ). The closed ring of TM segments observed in the first crystal structure suggested that something must move to clear a path for lateral substrate entry [34–37]. Only mutations that weaken TM5 packing with TM2 were found to enhance protease activity by up to ten-fold, thereby identifying the gate functionally [77, 81, 83]. This dramatic enhancement also revealed that gate opening is the rate-limiting step for intramembrane proteolysis. Molecular dynamics simulations and structural analysis in a bicelle also suggest membrane thinning surrounding GlpG, but its mechanistic implications remain unclear [84, 85]. Investigating the role of the membrane in greater detail promises to reveal the defining features of the rhomboid proteolysis system.
The rhomboid gene was identified in the Drosophila screens of the late 1970s and early 1980s , and it was cloned and sequenced about a decade later . It took another decade, until 2001, for its biochemical function as an intramembrane serine protease to be revealed . It has now been a decade since that turning point, and advances in the intervening period have culminated in rhomboid proteases becoming widely regarded as the best understood of all intramembrane proteases . Biochemical insights and defined roles in parasitic protozoa (reviewed in ) place rhomboid study on the cusp of becoming applicable in a therapeutic setting. A major lingering obstacle is a rudimentary understanding of its unusual enzymatic mechanism, but these questions are being pursued intensively, and momentum towards a sophisticated understanding is building .
By contrast, defining the cellular roles of rhomboid proteases has been a slow process . Although even early biochemical insights have led to the identification of substrates that can be cleaved, whether these candidates are indeed physiological targets, and if so, whether they truly represent a major rhomboid function, remain unknown. For example, although the study of human RHBDL2 over the past 7 years has uncovered at least three well-cleaved substrates (thrombomodulin , B-type ephrins , and EGF ), it is still unclear which, if any, are actual physiological targets, and whether cleavage represents a bona fide contribution to cellular function. Perhaps the most humbling example is E. coli GlpG, whose atomic details have been revealed in over a dozen structures and countless mutants, yet its cellular function remains a complete mystery . In reality, it is not the ability to find substrate candidates but rather their validation that has proven to be the bottleneck in these studies. Refining search algorithms is unlikely to contribute much towards solving this problem. The urgent need is for approaches with which to study enzymes under physiological settings on a higher throughput scale. This, in turn, will focus biochemical investigations by providing physiological targets and new functional contexts.
We are grateful to Rosanna Baker for help with illustrating Figure 4. Work in our laboratory is supported by the Howard Hughes Medical Institute, and the David and Lucile Packard Foundation.